Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Clinical Nephrology

Anti-nephrin antibodies in minimal change disease: Case report series

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMaša KnehtlNPNejc PikoTPTadej Petreski

Discussion

Loading...

Member takes

Overview

Case series reveals autoantibodies in minimal change disease, suggesting rituximab may benefit treatment-resistant patients.

Key Points

  • Autoantibodies were detected in patients with minimal change disease, indicating a potential autoimmune link.
  • Treatment with rituximab may offer an alternative for patients who are resistant to standard therapies.
  • The study highlights a subgroup of patients with drug-related adverse effects that complicate their condition.
  • Findings underscore the need for further investigation into targeted therapies for relapsing disease.

Cite This Study

Knehtl et al. (2025) studied this question.

synapsesocial.com/papers/692b9d8d1d383f2b2a3799bfhttps://doi.org/10.5414/cnp104s12
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1#1639 Nephrotic syndrome with anti-nephrin antibodies—case report of minimal change glomerulonephritis2024
  2. 2Association between anti-nephrin autoantibodies and disease activity in minimal change disease2026
  3. 3Clinical Characteristics of Nephrin Autoantibody-Positive Minimal Change Disease in Older Adults2024 · 8 citations
  4. 4Anti-CD20 therapies and anti-nephrin autoantibodies in IgA nephropathy with minimal change disease2026
  5. 5WCN24-1037 Minimal change glomerulonephritis steroid-dependent nephrotic syndrome treated with Rituximab2024 · 1 citations